Next Generation Antibody Therapeutics

下一代抗体疗法

• 批准号: nhmrc : GNT1157744
• 负责人: A/Pr Daniel Christ
• 金额: $ 71.73万
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/generation-antibody-therapeutics/1349240
• 关键词: Next; Generation; Antibody; Therapeutics

This research will focus on an important problem, namely the limitations on specificity and persistence of human antibodies. Although often perceived as a perfect 'lock-and-key' phenomenon, many antibodies in fact display limited specificity and interact with unrelated targets resulting in short persistence and off-target effects. By deciphering mutational and structural mechanisms unpinning antibody specificity, my research will advance the development of next generation antibody therapeutics.

这项研究将集中在一个重要的问题上，即人类抗体的特异性和持久性的局限性。尽管通常被认为是完美的“锁和钥匙”现象，但许多抗体实际上显示出有限的特异性，并与不相关的靶标相互作用，导致短暂的持久性和脱靶效应。通过破译突变和结构机制解除抗体特异性，我的研究将推动下一代抗体治疗的发展。